Richard Brudnick

Mr. Brudnick has held senior positions in the areas of Portfolio Strategy & Business Development and Corporate Development in a number of pharmaceutical companies and currently serves as Chief Business Officer at Prime Medicine, Inc, a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address a wide spectrum of diseases.

Mr. Brudnick received a B.S. and M.S. in Management Science from the Massachusetts Institute of Technology.